Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05592379 · ClinicalTrials.gov registry record · Phase 1
Consciousness, Psilocybin, and Well-Being
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05592379 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 6 participants.
The verdict
NCT05592379, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
Interventions
- OTHER Saline
- DRUG Psilocybin
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2025-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05592379
The ClinicalTrials.gov registry entry for NCT05592379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT05592379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05592379 about?
NCT05592379 is a clinical study titled "Consciousness, Psilocybin, and Well-Being". This study is being done to identify a dosing strategy that will allow IV psilocybin to be administered to sleeping participants without awakening them.
What is the current status of trial NCT05592379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-11-07. Estimated completion is 2025-02-19.
What interventions are being tested in trial NCT05592379?
The interventions under investigation include: Saline (OTHER), Psilocybin (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT05592379?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.